Secondary failure: immune responses to approved protein therapeutics. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Lagassé, H.A. Daniel; McCormick, Quinn; Sauna, Zuben E.
• Is Part Of: Trends in molecular medicine. Volume 27:Issue 11(2021)
• Page Start: 1074
• Page End: 1083
• Publication Date: 2021-11
• Subjects: immunogenicity -- therapeutic proteins -- anti-drug antibodies -- neutralizing antibodies; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; Physiology, Pathological -- Periodicals; 572.8
• DOI: 10.1016/j.molmed.2021.08.003
• Languages: English
• ISSNs: 1471-4914

Abstract

Abstract : Recombinant therapeutic proteins are a broad class of biological products used to replace dysfunctional human proteins in individuals with genetic defects (e.g., factor VIII for hemophilia) or, in the case of monoclonal antibodies, bind to disease targets involved in cancers, autoimmune disorders, or other conditions. Unfortunately, immunogenicity (immune response to the drug) remains a key impediment, potentially affecting the safety and efficacy of these therapeutics. Immunogenicity risk is routinely evaluated during the licensure of therapeutic proteins. However, despite eliciting anti-drug immune responses in at least some patients, most protein drugs are nevertheless licensed as they address unmet medical needs. The pre-licensure immunogenicity assessments of therapeutic proteins are the subject of numerous reviews and white papers. However, observation and clinical management of the immunogenicity of approved therapeutic proteins face additional challenges. We survey the immunogenicity of approved therapeutic proteins, discuss the clinical management of immunogenicity, and identify the challenges to establishing clinically relevant immunogenicity assays for use in routine clinical practice. Highlights: Immunogenicity can compromise the safety and/or efficacy of therapeutic protein products, and is a priority issue for regulatory agencies. In addition to poor patient outcomes, the social and economic costs associated with neutralizing antibodies are considerable. Reliable assays for monitoring anti-drug antibodies (ADAs) and neutralizing antibodies post-licensure are lacking for most therapeutic proteins.